Idera Pharmaceuticals, Inc.

Get the IDRA Research Report and Also Receive Our Top Trades for 2016! IMO-2125 and IMO-8400 are the Company’s lead clinical development drug candidates. IMO-2125 is an oligonucleotide-based agonist of Toll-like receptor (TLR) 9. IMO-8400 is an oligonucleotide-based...

Innocoll Holdings

Get the INNL Research Report and Also Receive Our Top Trades for 2016! Innocoll reported a net loss attributable to ordinary shares of $3.8 million, or $0.13 per share, for the fourth quarter of 2016, compared to a loss of $7.7 million, or $0.33 per share for the...

Moleculin Biotech, Inc.

Get the MBRX Research Report and Also Receive Our Top Trades for 2016! On March 22nd, the company announced its lead candidate, Annamycin (also known as “Liposomal Annamycin”), an anthracycline, has received Orphan Drug Designation by the U.S. Food and Drug...

OvaScience Inc.

Get the OVAS Research Report and Also Receive Our Top Trades for 2016! In December 2016, OvaScience announced its decision to continue the development of OvaPrime. OvaScience is currently evaluating OvaPrime in a prospective, blinded, randomized and controlled...

Aevi Genomic Medicine, Inc.

Get the GNMX Research Report and Also Receive Our Top Trades for 2016! On March 20th, the company announced top-line results from the SAGA trial of AEVI-001 (oral non-stimulant) in adolescents with mGluR mutation positive (mGluR+) ADHD. Although AEVI-001 did not meet...

OraSure Technologies, Inc.

Get the OSUR Research Report and Also Receive Our Top Trades for 2016! OraSure Technologies will replace G&K Services Inc. in the S&P SmallCap 600 effective prior to the open on Thursday, March 23. S&P 500 constituent Cintas Corp. is acquiring G&K...